A worldwide, exclusive license is being granted to develop and commercialize enzyme replacement therapies using proprietary platform technology.

At AAPS PharmSci 360 2025, Elly Zhou says digital twins helped forecast the effects of drugs on human drugs via a digital control arm.

Thermo Fisher’s Jennifer Cannon reviews the first year of the company’s Accelerator Drug Development suite of services and ...

A streamlined workflow using Six Sigma's DMAIC methodology was developed to identify and mitigate visible particles in ...

Steve will be monitoring the Rapid Fires: AI/ML in Bioanalysis session on Monday, Nov. 10, 2025 at 3PM CT at AAPS PharmSci ...

3D printing technology enables precise drug design, personalized dosing, and versatile release modes, benefiting patient-centric treatments. At AAPS PharmSci 360, Xialing Li, PhD, says 3D-printed ...

To learn more about how method validation is performed for biomarker bioanalysis, Pharmaceutical Technology ® spoke with ...

In the life sciences industry, the journey from discovery to delivery is only as strong as the supply chain and distribution ...

Editor's note: this interview was originally published on BioPharmInternational.com.

Ex vivo lung perfusion (EVLP) provides a platform for testing therapies but faces challenges in standardizing drug evaluation. At AAPS PharmSci 360, Xuanzi Zhou says digital twins accurately predict ...

Two major themes cut across the week’s news: the profound integration of advanced technology, particularly Artificial ...

Siddhant Sojitra, Alexion, defines in an AAPS PharmSci 360 2025 presentation an agitation model to reliably test stability for early-stage biologics.